跳至主要内容
临床试验/NCT00402038
NCT00402038已完成3 期

A Double-Blind, Phase 3, Two-Week, Placebo Controlled Study of Methylnaltrexone(MNTX) for the Relief of Constipation Due to Opioid Therapy in Advance Medical Illness.

Bausch Health Americas, Inc.1 个研究点 分布在 1 个国家目标入组 134 人开始时间: 2004年2月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
134
试验地点
1
主要终点
Laxation within four hours of a single dose of SC MNTX and efficacy of SC MNTX every other day over a 1 week period.

研究概览

简要总结

To determine the efficacy of subcutaneous MNTX to relieve opioid-induced constipation in patients with advanced medical illness.

详细描述

This is a multi-center, double-blind, randomized parallel group study conducted in patients with advanced medical illness and opioid-induced constipation. Eligible patients are randomly assigned to receive SC doses of either MNTX, dose 1 or placebo every other day for 2 weeks. At Day 8, eligible patients, if allowed, could be escalated to a a higher dose of MNTX.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 18 years of age and older
  • Negative pregnancy test (serum or urine) at screening for all women of childbearing potential
  • Advanced Medical Illness (i.e., terminal illness, such as incurable cancer or end of stage AIDS) with life expectancy of ≥ 1 month
  • patient must sign ICF

排除标准

  • Women who are pregnant and/or nursing
  • Previous treatment with MNTX
  • Participation in any other studies involving investigational products within 30 days prior to screening

研究组 & 干预措施

Arm 1

Experimental

干预措施: SC Methylnaltrexone (Drug)

Arm 2

Placebo Comparator

干预措施: SC Placebo (Drug)

结局指标

主要结局

Laxation within four hours of a single dose of SC MNTX and efficacy of SC MNTX every other day over a 1 week period.

时间窗: 2 weeks

To determine the efficacy of a single dose of SC MNTX compared with placebo in inducing laxation within 4 hours. To determine the efficacy of SC MNTX every other day over a 1-week treatment period in relieving OIC in patients with AMI.

次要结局

未报告次要终点

研究者

申办方类型
Industry

研究点 (1)

Loading locations...

相似试验

Study of Methylnaltrexone (MNTX) for the Relief of... | 临床试验